- Investing.com
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.
Pegozafermin Promise | Explore 89bio's lead candidate pegozafermin, poised to disrupt MASH and SHTG treatment landscapes with its potential billion-dollar market opportunities |
Clinical Milestones | Delve into 89bio's ongoing Phase 3 trials and the significance of upcoming competitor data in shaping the company's future prospects |
Market Dynamics | Learn how 89bio navigates the evolving MASH treatment landscape, positioning pegozafermin against emerging therapies and potential market shifts |
Financial Outlook | Analyst price targets range from $12 to $49, with potential for significant upside based on clinical outcomes and market positioning |
Metrics to compare | ETNB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipETNBPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.0x | −2.7x | −0.6x | |
PEG Ratio | 0.04 | 0.00 | 0.00 | |
Price/Book | 2.6x | 0.7x | 2.6x | |
Price / LTM Sales | - | 131.3x | 3.3x | |
Upside (Analyst Target) | 202.5% | 136.8% | 39.1% | |
Fair Value Upside | Unlock | 6.6% | 5.4% | Unlock |